Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 967286, 9 pages
http://dx.doi.org/10.1155/2015/967286
Research Article

Chemosensitivity of Anaplastic Thyroid Cancer Based on a Histoculture Drug Response Assay

Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo 150-8308, Japan

Received 7 December 2014; Revised 4 March 2015; Accepted 5 March 2015

Academic Editor: Constantinos Pantos

Copyright © 2015 Takashi Uruno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Smallridge and J. A. Copland, “Anaplastic thyroid carcinoma: pathogenesis and emerging therapies,” Clinical Oncology, vol. 22, no. 6, pp. 486–497, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Sugitani, A. Miyauchi, K. Sugino, T. Okamoto, A. Yoshida, and S. Suzuki, “Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC research consortium of Japan cohort study of 677 patients,” World Journal of Surgery, vol. 36, no. 6, pp. 1247–1254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. R. C. Smallridge, K. B. Ain, S. L. Asa et al., “American thyroid association guidelines for management of patients with anaplastic thyroid cancer,” Thyroid, vol. 22, no. 11, pp. 1104–1139, 2012. View at Publisher · View at Google Scholar
  4. K. Shimaoka, D. A. Schoenfeld, W. D. Dewys, R. H. Creech, and R. DeConti, “A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma,” Cancer, vol. 56, no. 9, pp. 2155–2160, 1985. View at Google Scholar
  5. T. Furukawa, T. Kubota, and R. M. Hoffman, “Clinical applications of the histoculture drug response assay,” Clinical Cancer Research, vol. 1, no. 3, pp. 305–311, 1995. View at Google Scholar · View at Scopus
  6. T. Kubota, N. Sasano, O. Abe et al., “Potential of the histoculture drug-response assay to contribute to cancer patient survival,” Clinical Cancer Research, vol. 1, no. 12, pp. 1537–1543, 1995. View at Google Scholar · View at Scopus
  7. R. Kato, K. Hasegawa, Y. Achiwa et al., “Predicting nedaplatin sensitivity of cervical cancer using the histoculture drug response assay,” European Journal of Gynaecological Oncology, vol. 32, no. 4, pp. 381–386, 2011. View at Google Scholar · View at Scopus
  8. T. Yoshimasu, F. Ohta, S. Oura et al., “Histoculture drug response assay for gefitinib in non-small-cell lung cancer,” General Thoracic and Cardiovascular Surgery, vol. 57, no. 3, pp. 138–143, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Yoshimasu, S. Oura, I. Hirai et al., “Data acquisition for the histoculture drug response assay in lung cancer,” Journal of Thoracic and Cardiovascular Surgery, vol. 133, no. 2, pp. 303–308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. S. W. Lee, Y. M. Kim, M. B. Kim et al., “In vitro chemosensitivity using the histoculture drug response assay in human epithelial ovarian cancer,” Acta Medica Okayama, vol. 66, no. 3, pp. 271–277, 2012. View at Google Scholar · View at Scopus
  11. R. A. Vescio, C. H. Redfern, T. J. Nelson, S. Ugoretz, P. H. Stern, and R. M. Hoffman, “In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 14, pp. 5029–5033, 1987. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Singh, R. Li, L. Xu et al., “Prediction of survival in patients with head and neck cancer using the histoculture drug response assay,” Head and Neck, vol. 24, no. 5, pp. 437–442, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. K. T. Robbins, K. M. Connors, A. M. Storniolo, C. Hanchett, and R. M. Hoffman, “Sponge-gel-supported histoculture drug-response assay for head and neck cancer: correlations with clinical response to cisplatin,” Archives of Otolaryngology—Head and Neck Surgery, vol. 120, no. 3, pp. 288–292, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. P.-S. Jung, D.-Y. Kim, M.-B. Kim et al., “Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution,” Anticancer Research, vol. 33, no. 3, pp. 1029–1034, 2013. View at Google Scholar · View at Scopus
  15. T. Yoshimasu, S. Oura, I. Hirai et al., “In vitro evaluation of dose-response curve for paclitaxel in breast cancer,” Breast Cancer, vol. 14, no. 4, pp. 401–405, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Yoshida, K. Sugino, I. Sugitani, and A. Miyauchi, “Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination,” World Journal of Surgery, vol. 38, no. 9, pp. 2311–2316, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Akaishi, K. Sugino, W. Kitagawa et al., “Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma,” Thyroid, vol. 21, no. 11, pp. 1183–1189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. I. J. Nixon, A. R. Shaha, and M. R. Tuttle, “Targeted therapy in thyroid cancer,” Current Opinion in Otolaryngology and Head and Neck Surgery, vol. 21, no. 2, pp. 130–134, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. K. B. Ain, M. J. Egorin, and P. A. DeSimone, “Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group,” Thyroid, vol. 10, no. 7, pp. 587–594, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Higashiyama, Y. Ito, M. Hirokawa et al., “Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma,” Thyroid, vol. 20, no. 1, pp. 7–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. W. Lee, Y.-M. Kim, M.-B. Kim et al., “Chemosensitivity of uterine cervical cancer demonstrated by the histoculture drug response assay,” Tohoku Journal of Experimental Medicine, vol. 219, no. 4, pp. 277–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Foo and F. Michor, “Evolution of acquired resistance to anti-cancer therapy,” Journal of Theoretical Biology, vol. 355, pp. 10–20, 2014. View at Publisher · View at Google Scholar